A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-02-27
Adverse events
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-18 (study day 34); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-05-23 (study day 69); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-06-08 (study day 85); relationship: N
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-13 (study day 120); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-24 (study day 193); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-06 (study day 236); relationship: N
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-12-02 (study day 262); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 269); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-19 (study day 310); relationship: N
Data queries
No data queries.